Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96

Benzinga · 1d ago
Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.